ArticleInternational urology and nephrology2026
Kidney transplantation outcomes in recipients with end-stage kidney disease due to primary vesicoureteral reflux: a case-control study.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeVesicoureteral reflux (VUR) may lead to reflux nephropathy and end-stage kidney disease (ESKD). Whether ESKD due to primary VUR identifies kidney transplant recipients at higher long-term graft risk remains incompletely defined, particularly when VUR phenotype, bladder status, reconstructive history, and infection burden are not captured.
methodsWe performed a retrospective 1:3 case-control study of kidney transplant recipients with ESKD attributed to primary VUR and non-VUR controls transplanted at a tertiary center. Patients whose primary ESKD etiology was bladder exstrophy, epispadias, posterior urethral valves, neurogenic bladder, prior cystectomy, complex congenital lower urinary tract anomalies, or myelomeningocele were not included in the primary VUR cohort. The dataset captured age at ESKD, VUR grade and laterality, dominant renal involvement, native ureteral reimplantation, native nephrectomy, clean intermittent catheterization, bladder augmentation, urinary reconstruction, and UTI episodes during the 12 months before and after transplantation. The primary endpoint was death-censored graft failure.
resultsThe cohort included 32 primary VUR recipients and 96 controls. Median age at ESKD among VUR recipients was 31 years (IQR 22.8-39.0), and median age at transplantation was 39 years (IQR 30-46). VUR grade was IV in 9/32 recipients (28.1%) and V in 23/32 recipients (71.9%); VUR was bilateral in 22/32 (68.8%). Native ureteral reimplantation/UCNA was recorded in 25/32 (78.1%), native nephrectomy in 13/32 (40.6%), clean intermittent catheterization in 12/32 (37.5%), and bladder augmentation in 6/32 (18.8%). UTI burden decreased from 48 episodes during the 12 months before transplantation to 15 episodes during the 12 months after transplantation; recurrent UTI decreased from 15/32 (46.9%) to 1/32 (3.1%). Post-transplant cystographic evaluation was not routine; graft VUR was documented in no patient. Graft failure occurred in 14/32 VUR recipients (43.8%) and 46/96 controls (47.9%). Estimated 10 year death-censored graft survival was 66.8% in the VUR group and 65.3% in controls (log-rank p = 0.977). VUR was not associated with graft failure in the crude Cox model (HR 1.01, 95% CI 0.55-1.84; p = 0.978) or in an exploratory adjusted model (HR 0.88, 95% CI 0.48-1.62; p = 0.677).
conclusionIn this single-center cohort, ESKD due to primary VUR was not associated with inferior death-censored kidney graft survival. These phenotype data indicate that the prognostic question in VUR is not the diagnostic label alone, but the combination of reflux severity, bladder/reconstructive status, native urinary tract management, and infection burden.
Indexed as
Identifiers
42477273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.